Showing results (301-310 of 470) with videos related to
Sort By:
Pageof 47
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast CancerMatthew P Goetz, Erika P Hamilton, Mario Campone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesMatthew P Goetz, James M Rae, Vera J Suman, et al.JAMA|April 5, 2012
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trialSteven R Alberts, Daniel J Sargent, Suresh Nair, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II TrialThomas E Mürdter, Werner Schroth, Matthew P Goetz, et al.Scientific Reports|January 12, 2023
PDJ amplicon in triple negative breast cancerAlexander S Roesler, Smriti Malasi, Lori Koslosky, et al.Pharmacogenetics and Genomics|February 26, 2015
Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifenStephanie L Safgren, Vera J Suman, Matthew L Kosel, et al.JCO Precision Oncology|March 9, 2022
Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid TumorsPashtoon M Kasi, Gordon Fehringer, Hiroya Taniguchi, et al.ESMO Open|November 24, 2020
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinomaAndreas Seeber, Kai Zimmer, Florian Kocher, et al.Cell Metabolism|September 4, 2018
Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle PathwayKiran Kurmi, Sadae Hitosugi, Jia Yu, et al.Breast Cancer Research : BCR|November 23, 2017
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclibNusayba Bagegni, Shana Thomas, Ning Liu, et al.Pageof 47